|Application ||WB, IHC-P, IHC-F, IF, FC, IP|
|Calculated MW||207721 Da|
|Purification||Purified IgG prepared by affinity chromatography on Protein G|
|Immunogen||Recombinant protein corresponding to the N-Terminal region of human BRCA1|
|Shelf Life||18 months from date of despatch.|
|Other Names||Breast cancer type 1 susceptibility protein, 6.3.2.-, RING finger protein 53, BRCA1, RNF53|
|Target/Specificity||Mouse anti-Human BRCA1 antibody, clone MS110 recognizes an epitope within the 304 amino acid N-Terminal (NT) region of human BRCA1, otherwise known as Breast cancer type 1 susceptibility protein, a tumor suppressor gene and major player in DNA damage repair, predominantly expressed in the nucleus during the S/G2 phase of the cell cycle. Along with BRCA2, BRCA1 is a high risk gene which is associated with hereditary breast and ovarian cancers, particularly at a younger age of diagnosis. Women carrying the BRCA1 mutation have a 50-95% chance of developing breast cancer in later life, but genetic screening and increased awareness of preventative surgery, can reduce this risk significantly. Deleterious BRCA1 mutations may also increase the risk of other cancers in both males and females including pancreatic cancer, although in males pancreatic and prostate cancer appear to be more strongly associated with BRCA2 gene mutations. BRCA1 is a key marker of triple-negative breast cancer/TNBC (ER-/PR-/HER2-), a high risk aggressive cancer which makes up about 15% of invasive breast cancers, and which lacks the benefit of specific therapy that targets the three major proteins ER/PR/HER2. Triple-negative tumors are predominantly basal-like, poorly differentiated and of higher histological grade. Younger women have an increased rate of basal or BRCA related TNBC, compared with the higher proportion of apocrine, normal-like and rare subtypes of TNBC, seen in older women. Mouse anti-human BRCA1 antibody, clone MS110 is suitable for use in both immunohistochemical and immunofluorescence staining of human breast and ovarian tissue, and clone MS110 is a widely recognized antibody for use in cancer studies.|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Human BRCA1 (N-Terminal) Antibody, clone MS110 is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Scully, R. et al. (1996) Location of BRCA1 in human breast and ovarian cancer cells.Science 272: 123-125 2. Yoshikawa, K. et al. (1999) Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.Clin. Cancer Res. 5: 1249-1261 3. Scully, R. et al. (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells.Cell. 88: 265-75. 4. Chen, J. et al. (2000) Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage.Cancer Res. 60: 5037-9. 5. Fraser, J.A. et al. (2003) A role for BRCA1 in sporadic breast cancer.Br J Cancer. 88: 1263-70. 6. Kleiman, F.E. et al. (2005) BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II.Genes Dev. 19: 1227-37. 7. Pageau, G.J. and Lawrence, J.B. (2006) BRCA1 foci in normal S-phase nuclei are linked to interphase centromeres and replication of pericentric heterochromatin.J Cell Biol. 175: 693-701.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.